Search results for "Hodgkin"

showing 10 items of 180 documents

Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials

2016

IF 6.671; International audience

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologySurvival impact[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyABVD[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHodgkin lymphomaBEACOPPChimiothérapie
researchProduct

Factors related to non-Hodgkin's lymphoma long-time to treatment initiation and impact on survival in a population based study in France: is there a …

2016

International audience

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyNon-Hodgkin's lymphomaHematologyComputingMilieux_MISCELLANEOUS
researchProduct

Facteurs épidémiologiques influençant la survie dans le lymphome à cellules du manteau

2017

Mantle Cell Lymphoma (MCL) is a recently defined entity, typically characterised by the genetic translocation t(11 ;14)(q13 ;q32) and counting for 2 - 10% of all non-Hodgkin Lymphomas. With a median survival between 3 and 5 years after diagnosis, MCL is an agressive disease and despite the recent therapeutic advances little in know about its prognostic factors. Some studies had investigated clinicopathological features and new treatment strategies, but there is a lack of knowledge regarding the impact of lifestyle and environnemental factors on outcome of MCL patients. From 2008 to 2012, the LYSA Group conducted in France two prospective multi center clinical trials on MCL : LM manteau 2010…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySurvivalMantle Cell LymphomaNon-Hodgkin LymphomaPopulation-Based studyPrognostic factorsLymphome à Cellules du ManteauClinical TrialEssai CliniqueSurvieFacteurs pronosticsEtude en population généraleLymphome non-Hodgkinien[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas,

2014

Histone deacetylases (HDAC) extensively contribute to the c-Myc oncogenic program, pointing to their inhibition as an effective strategy against c-Myc-overexpressing cancers. We, thus, studied the therapeutic activity of the new-generation pan-HDAC inhibitor ITF2357 (Givinostat®) against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas (B-NHLs). ITF2357 anti-proliferative and pro-apoptotic effects were analyzed in B-NHL cell lines with c-Myc translocations (Namalwa, Raji and DOHH-2), stabilizing mutations (Raji) or post-transcriptional alterations (SU-DHL-4) in relationship to c-Myc modulation. ITF2357 significantly delayed the in vitro growth of all B-NHL cell lines by inducing G1 c…

c-MycmicroRNAnon-Hodgkin lymphomac-Myc; histone deacetylase inhibitors; microRNA; non-Hodgkin lymphomahistone deacetylase inhibitor
researchProduct

VEBEP REGIMEN IN PATIENTS (PTS) WITH HD AND HIV INFECTION(HD-HIV): FINAL RESULTS OF A PHASE II STUDY OF THE ITALIAN COOPERATIVE GROUP ON AIDS AND TUM…

2011

chemotherapyHIV infectionHodgkin' disease
researchProduct

Bone marrow biopsy in Hodgkin's lymphoma

2004

In the study of patients with Hodgkin's lymphoma (HL) the evaluation of bone marrow biopsy (BMB) can be difficult. In this review we analyze the main diagnostic features and the clinical risk factors of BM involvement. Although the role of BMB is criticized by some authors, its value is irreplaceable in the staging of HL and in the diagnosis of primary medullary HL. The Ann Arbor staging committee criteria should be revised and updated in the light of the current immunohistochemical studies that give a fundamental help in the diagnostic process. A single BMB should be adequate for diagnosis in most instances. In cases of suspicious involvement a controlateral BMB could be performed.

medicine.medical_specialtyAnn Arbor stagingmedicine.diagnostic_testMedullary cavitybusiness.industryHematologyGeneral MedicineHodgkin's lymphomamedicine.diseaseLymphomaBone marrow examinationImmunophenotypingmedicine.anatomical_structureBiopsyMedicineRadiologyBone marrowbusinessEuropean Journal of Haematology
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Oral non-Hodgkin’s lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate

2015

Oral non-Hodgkin’s lymphomas (O-NHLs) are a rare group of diverse lymphoid tissue malignancies and represent less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer’s-ring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. O-NHLs share the same risk factors. This case report describes a patient with O-NHL which was possibly linked to the combination of methotrexate and etanercept for the treatment of her rheumatoid arthritis. To our knowledge this is probably among the fir…

medicine.medical_specialtyCase ReportOdontologíaMalignancyEtanerceptimmune system diseaseshemic and lymphatic diseasesmedicineMedical historyOral mucosaGeneral DentistryOral Medicine and Pathologybusiness.industrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludNon-Hodgkin's lymphomaLymphomastomatognathic diseasesmedicine.anatomical_structureRheumatoid arthritisUNESCO::CIENCIAS MÉDICASImmunologyMethotrexatebusinessmedicine.drug
researchProduct

Computer-assisted interpretation of flow cytometry data in hematology.

1996

A computer program has been developed for computer-assisted diagnosis (including subclassification) of flow cytometry data of acute leukaemias and non-Hodgkin lymphomas by means of artificial intelligence. The knowledge base for the system has been formulatedas semantic networks that describe physiological hematopoiesisas well as the pathological situation (eg., aberrant antigen expression) of hematological disorders. The semantic networks reflect the hierarchy of cells and their occurrence in diseases, the normal and pathological antigen expression patterns of cells, cell maturation, and the frequency of cell populations in normal blood and bone marrow. Using these semantic networks, the d…

medicine.medical_specialtyCellBiophysicsExpert SystemsDiseaseCell MaturationPathology and Forensic MedicineFlow cytometryEndocrinologyAntigenInternal medicineMedicineHumansDiagnosis Computer-AssistedPathologicalHematologyLeukemiamedicine.diagnostic_testbusiness.industryLymphoma Non-HodgkinReproducibility of ResultsCell BiologyHematologyFlow Cytometrymedicine.anatomical_structureData Interpretation StatisticalImmunologyAcute DiseaseBone marrowbusinessCytometry
researchProduct

Splenic respiratory gas exchange and glucose uptake in patients with splenomegaly in hypersplenism and Hodgkin's disease.

1977

Blood samples are taken from the splenic artery, vein and pulp of patients suffering from Hodgkin's disease (n=10) or hypersplenism (n=7) and undergoing splenectomy. In these samples, the relevant parameters of the respiratory gas exchange as well as glucose and lactate concentrations are determined. In hypersplenism (mean splenic wet weight: 543 g) the mean oxygen consumption of the splenic tissue amounts to 0.9 ml O2/100 g/min taking into account a mean splenic blood flow of 80 ml/100 g/min. The glucose uptake and the lactate release are 9 mg/100 g/min and 5.5 mg/100 g/min, respectively. These values are in close agreement with the results obtained in the normal and undisturbed spleen in …

medicine.medical_specialtyErythrocytesGlucose uptakeRespiratory gas exchangechemistry.chemical_elementSpleenSplenic arteryOxygenHypersplenismVeinsOxygen Consumptionmedicine.arteryInternal medicineDrug DiscoverymedicineHumansIn patientGenetics (clinical)business.industryGeneral MedicineVenous bloodHydrogen-Ion ConcentrationHodgkin DiseaseSurgerymedicine.anatomical_structureEndocrinologyGlucosechemistrySplenic TissueSplenomegalyLactatesMolecular MedicinebusinessSplenic ArterySpleenKlinische Wochenschrift
researchProduct